NCT07677267Recruiting

A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

Novartis Pharmaceuticals

Start Date

6/30/2026

Completion Date

11/30/2026

Summary

The aim of this study is to assess treatment patterns, characteristics, and clinical outcomes among adults with metastatic castration-resistant prostate cancer (mCRPC) who have previously received ≥1 androgen receptor pathway inhibitor (ARPI), ≥1 taxane, and 177Lu-PSMA-617 in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.

Eligibility Criteria

Age Range: 18 years to 115 years

Inclusion criteria: * Evidence of 177Lu-PSMA-617 use on or after 01 January 2021. * Evidence of treatment with ≥1 ARPI, before 177Lu-PSMA-617. * Evidence of treatment with ≥1 taxane, before or after 177Lu-PSMA-617. * Diagnosis of mCRPC prior to or on the index date. The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617. * Age ≥18 years at index. Exclusion criteria: • None.

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Prostatic Neoplasms, Castration-Resistant

Locations

Novartis

East Hanover, New Jersey 07936

United States